Which patients are suitable for Verquvo?

The VICTORIA study evaluated the efficacy and safety profile of vericiguat in adult patients with symptomatic chronic heart failure (New York Heart Association class II–IV) and left ventricular ejection fraction less than 45% following a worsening heart failure event. A worsening chronic heart failure event was defined as heart failure hospitalisation within 6 months before randomisation or use of outpatient IV diuretics for heart failure within 3 months before randomisation.
Patients were treated up to the target maintenance dose of vericiguat 10 mg once daily, or matching placebo, in combination with other heart failure therapies. At baseline, more than 99% of patients were treated with other heart failure therapies which included beta blockers (93%), angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) (73%), mineralocorticoid receptor antagonists (MRA) (70%), a combination of an angiotensin receptor and neprilysin inhibitor (ARNI) (15%), ivabradine (6%), implantable cardiac defibrillators (28%), and biventricular pacemakers (15%).
Please see ‘How is Verquvo prescribed?’ for further information on dosing and method of administration, and on special warnings and precautions for use, and always refer to the Summary of Products for full details on how to prescribe vericiguat.

PP-VER-GB-0031 | November 2022

“Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”